Aug 31, 2026 08:32AM
Aug 31, 2026 08:30AM
Aug 20, 2026 08:00AM
Aug 13, 2026 04:15PM
Aug 6, 2026 08:01AM
Aug 6, 2026 08:00AM
Jul 14, 2026 08:01AM Ensysce gets $5.3M final installment of $15M NIDA grant
Jul 14, 2026 08:00AM
Jun 26, 2026 08:02AM
Jun 26, 2026 08:00AM
May 15, 2026 04:15PM
May 12, 2026 08:09AM
May 12, 2026 08:00AM
May 8, 2026 08:00AM Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Apr 16, 2026 08:04AM
Apr 16, 2026 08:00AM
Apr 9, 2026 06:13AM
Apr 7, 2026 08:17AM
Apr 7, 2026 08:00AM
Mar 31, 2026 06:51AM
Mar 30, 2026 04:50PM Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 4, 2026 08:45AM
Mar 3, 2026 08:02AM
Mar 3, 2026 08:00AM
Feb 25, 2026 08:00AM
Feb 23, 2026 08:00AM
Jan 28, 2026 08:02AM
Jan 28, 2026 08:00AM Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Jan 21, 2026 08:03AM
Jan 21, 2026 08:00AM
Jan 8, 2026 08:00AM
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 9, 2025 08:00AM
Dec 9, 2025 08:00AM Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Dec 2, 2025 08:05AM
Dec 2, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 17, 2025 08:06AM
Nov 17, 2025 08:05AM
Nov 16, 2025 11:46PM Ensysce Biosciences (ENSC) reported Q3 EPS
Nov 14, 2025 04:15PM
Sep 4, 2025 08:00AM
Aug 19, 2025 08:00AM
Aug 13, 2025 06:15PM
Aug 13, 2025 04:15PM
Jul 31, 2025 08:00AM
Jul 31, 2025 08:00AM Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Jul 16, 2025 08:00AM

443,846 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All